Advanced in Hydrocephalus due to Congenital Stenosis of Aqueduct of Sylvius

Dr. Michael Chicoine

The Curators Of The University Of Missouri
Columbia, MO
Advanced
in Hydrocephalus due to Congenital Stenosis of Aqueduct of Sylvius
Specialties:Neurosurgery
OverviewInsuranceLocationsClinical Research

Overview

Michael Chicoine is a Neurosurgery provider in Columbia, Missouri. Dr. Chicoine and is rated as an Advanced provider by MediFind in the treatment of Hydrocephalus due to Congenital Stenosis of Aqueduct of Sylvius. His top areas of expertise are Meningioma, Pituitary Tumor, Brain Tumor, Endoscopic Transnasal Transsphenoidal Surgery, and Endovascular Embolization.

His clinical research consists of co-authoring 126 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Neurosurgery
Licenses
Neurological Surgery in MO
Hospital Affiliations
Barnes Jewish Hospital
University Of Missouri Health Care
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Medica
  •  Humana

Locations

THE CURATORS OF THE UNIVERSITY OF MISSOURI
1 Hospital Dr, Columbia, MO 65212
573-882-4141

Additional Areas of Focus

Dr. Chicoine has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Pilot Study to Assess the Safety, Feasibility, and Immunogenicity of a Neoantigen-based Personalized in Patients With Newly Diagnosed, Unmethylated Glioblastoma
A Pilot Study to Assess the Safety, Feasibility, and Immunogenicity of a Neoantigen-based Personalized in Patients With Newly Diagnosed, Unmethylated Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: January 10, 2025
Intervention Type: Device, Biological, Drug
Study Drugs: Personalized neoantigen DNA vaccine, Plasmid encoded IL-12
Study Phase: Phase 1
A Phase I/II Dose-escalation and Dose-expansion Study of Disulfiram/Copper With Concurrent Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma
A Phase I/II Dose-escalation and Dose-expansion Study of Disulfiram/Copper With Concurrent Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug, Procedure, Radiation
Study Drugs: Disulfiram, Copper Gluconate, Temozolomide
Study Phase: Phase 1/Phase 2
A Phase Ib Study of Neoadjuvant Avelumab and Hypofractionated Proton Radiation Therapy Followed by Surgery for Recurrent Radiation-refractory Meningioma
A Phase Ib Study of Neoadjuvant Avelumab and Hypofractionated Proton Radiation Therapy Followed by Surgery for Recurrent Radiation-refractory Meningioma
Enrollment Status: Terminated
Publish Date: June 15, 2023
Intervention Type: Radiation, Drug, Procedure
Study Drug: Avelumab
Study Phase: Phase 1
ENRICH: A Multi-center, Randomized, Clinical Trial Comparing Standard Medical Management to Early Surgical Hematoma Evacuation Using Minimally Invasive Parafascicular Surgery (MIPS) in the Treatment of Intracerebral Hemorrhage (ICH).
ENRICH: A Multi-center, Randomized, Clinical Trial Comparing Standard Medical Management to Early Surgical Hematoma Evacuation Using Minimally Invasive Parafascicular Surgery (MIPS) in the Treatment of Intracerebral Hemorrhage (ICH).
Enrollment Status: Completed
Publish Date: May 10, 2023
Intervention Type: Procedure
Study Phase: Not Applicable
A Pilot Study to Assess the Safety, Feasibility, and Immunogenicity of a Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma
A Pilot Study to Assess the Safety, Feasibility, and Immunogenicity of a Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma
Enrollment Status: Terminated
Publish Date: October 27, 2021
Intervention Type: Procedure, Biological
Study Phase: Phase 1
A Pilot Study of Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Doxorubicin in the Treatment of Recurrent Glioblastoma Multiforme
A Pilot Study of Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Doxorubicin in the Treatment of Recurrent Glioblastoma Multiforme
Enrollment Status: Completed
Publish Date: August 27, 2021
Intervention Type: Device, Drug, Other
Study Phase: Phase 1
Prospective Multicenter Cohort Study Comparing Extent of Tumor Resection Between Microscopic Transsphenoidal Surgery and Fully Endoscopic Transsphenoidal Surgery for Nonfunctioning Pituitary Adenomas
Prospective Multicenter Cohort Study Comparing Extent of Tumor Resection Between Microscopic Transsphenoidal Surgery and Fully Endoscopic Transsphenoidal Surgery for Nonfunctioning Pituitary Adenomas
Enrollment Status: Completed
Publish Date: November 25, 2019
Intervention Type: Procedure
Study Phase: Not Applicable
A Multicenter Study of 5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor in Patients With Newly Diagnosed or Recurrent Malignant Gliomas: A Safety, Histopathology, and Correlative Biomarker Study
A Multicenter Study of 5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor in Patients With Newly Diagnosed or Recurrent Malignant Gliomas: A Safety, Histopathology, and Correlative Biomarker Study
Enrollment Status: Completed
Publish Date: February 25, 2019
Intervention Type: Drug, Procedure
A Phase II Study of MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors
A Phase II Study of MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors
Enrollment Status: Terminated
Publish Date: November 06, 2018
Intervention Type: Drug
Study Phase: Phase 2
A Pilot Study to Assess the Safety, Feasibility, and Preliminary Efficacy of a Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma
A Pilot Study to Assess the Safety, Feasibility, and Preliminary Efficacy of a Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma
Enrollment Status: Terminated
Publish Date: November 17, 2017
Intervention Type: Drug, Biological
Study Phase: Phase 1
View 9 Less Clinical Trials

126 Total Publications

Abdominal myosteatosis measured with computed tomography predicts poor outcomes in patients with glioblastoma.
Abdominal myosteatosis measured with computed tomography predicts poor outcomes in patients with glioblastoma.
Journal: Neuro-oncology advances
Published: January 10, 2025

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile